Radiotherapy for Pertussis: An Historical Assessment

Edward J. Calabrese, PhD¹, Gaurav Dhawan, MBBS, MPH, RBP², and Rachna Kapoor, MD, MPH³

Abstract
X-ray therapy was used to treat pertussis/whooping cough during a 13-year period from 1923 to 1936 in North America and Europe. Twenty studies from clinicians in the United States reported that approximately 1500 cases of pertussis were treated by X-ray therapy usually with less than 0.5 erythema dose. Young children (<3 years) comprised about 70% to 80% of the cases, with the age of cases ranging from as young as 1 month to 50 years. In general, symptoms of severe coughing, vomiting episodes, and spasms were significantly relieved in about 85% of cases following up to 3 treatments, while about 15% of the cases showed nearly full relief after only 1 treatment. The X-ray therapy was also associated with a marked reduction in mortality of young (<3 years) children by over 90%. Despite such reported clinical success from a wide range of experienced researchers, the use of X-rays for the treatment of pertussis in young children was controversial, principally due to concerns of exposure to the thymus and thyroid even with the availability of lead shielding. By the mid-1930s, the treatment of pertussis cases via vaccine therapy came to dominate the therapeutic arena, and the brief era of a radiotherapy option for the treatment of pertussis ended.

Keywords
pertussis, whooping cough, X-rays, radiotherapy, history of science, hormesis

Introduction
Pertussis was a dreaded disease, especially for the very young, having a high risk of death for infants under the age of less than a year. It is characterized by paroxysms of cough, inspiratory whoop, and posttussive vomiting, with more severe forms leading to apnea in infants. The mortality rate for children less than 1 year was about 40% in the early 1900s in the state of Massachusetts.¹ Besides this mortality risk, the nature of the disease was extremely challenging to the affected individual as well as to parents, trying to care for the child, with substantial episodes of extreme coughing and projectile vomiting. Furthermore, the disease was highly contagious, leading to strict quarantining of the affected child. Lack of availability of treatment for pertussis resulted in clinical and psychosocial burden for both patient and the community. Numerous drug experiments were tried to accelerate recovery and enhance survival; however, none of the experiments achieved a significant therapeutic utility. In 1906, hope for a potential treatment arose when the bacterial cause of pertussis was identified. In fact, numerous groups competed to create an effective vaccine, with the next 3 decades witnessing a type of biomedical/clinical roller coaster of expectation and vaccine inadequacy being the norm. By the mid-1930s, an accepted vaccine emerged using a whole cell preparation. This preparation, while broadly effective, would itself pose an array of potential health concerns, giving way to a cell-free preparation by 2000.² However, during the earlier decades of the 20th century, between the frantic use of a plethora of failed drug remedies and the adoption of an acceptable vaccine, there emerged a new hope of radiotherapy that resulted in a range of therapeutic possibilities. This article provides a historical assessment of therapeutic use of X-rays in the treatment of pertussis, including the origin of this proposed therapy and a review of the studies assessing its efficacy and associated health concerns. Based on the available data, we also assessed the consistency and robustness of the reported results and

¹ Environmental Health Sciences, University of Massachusetts, Amherst, MA, USA
² Research Compliance, University of Massachusetts, Mass Venture Center, Hadley, MA, USA
³ Saint Barnabas Medical Center, Livingston, NJ, USA

Corresponding Author:
Edward J. Calabrese, Environmental Health Sciences, Morrill I, N344, University of Massachusetts, Amherst, MA 01003, USA.
Email: edwardc@schoolph.umass.edu

Creative Commons CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
various proposed mechanisms that account for reported beneficial effects.

**Origin of X-Ray Treatment of Pertussis**

The first reported case of pertussis treated by X-rays in the United States occurred as a last resort rather than by design. The case involved the treatment of a young child who exhibited an extremely severe form of pertussis. During the course of disease, the child had been treated with some of the commonly employed drug treatments, without apparent success. In fact, the child had lost much weight, became acutely ill, and there was considerable concern about the development of pneumonia. Given this situation, the mother desperately pleaded with the treating physician for some other treatment. At this point, the physician indicated that he had tried everything except the use of X-rays. Since X-rays had recently received publicity in the apparent successful treatment of several other diseases, the mother pleaded for its use for her child. Despite the presence of considerable skepticism of its therapeutic efficacy, Drs Henry I. Bowditch and Ralph D. Leonard, on the medical staff of the Floating Hospital in Boston, Massachusetts, decided to treat the child with a “low” dose of X-rays, which they estimated to be about 1/10 of the erythema dose (ED; note 1). Although the occurrence of paroxysms was markedly reduced that evening, the symptoms recurred the next day with the same severity. A second identical X-ray treatment 48 hours after the first dose yielded a similar transitory improvement. Following a third identical dose at 48 hours after the second treatment, the paroxysms ceased, with no recurrence. As recounted in their 1925 report, the number of cases was 300, with about 80% showing significant clinical benefit. The number of patients treated via X-rays at the Boston Floating Hospital would increase to 850, with consistent clinical success still approximating 80%.5

Despite these striking findings, the use of the X-ray treatment of young children caused considerable concern for some treating physicians about potential adverse effects on the thymus and thyroid glands. Such concerns were raised by Cook8 and Percy15 who cautioned against giving multiple X-ray treatments to infants. Bowditch10 defended these treatments by stating that the doses were well under those known to produce skin burns or thymic or thyroid atrophy. Moreover, he stated that when desired, a lead shield was provided to cover the glandular areas. The position of Bowditch was supported in summary forms of Bowditch10 and Leonard.11 However, in the report of Bowditch10 the number of cases was 300, with about 80% showing significant clinical benefit. The number of patients treated via X-rays at the Boston Floating Hospital would increase to 850, with consistent clinical success still approximating 80%.5

Interest in the therapeutic use of X-rays for pertussis continued until a final paper was published by Liebman16 in 1936 concerning his 13 years’ experience in Montreal with approximately 170 patients with pertussis that started soon after learning of the original Bowditch report. It was during this time that sufficient progress had been made in the development and testing of a more reliable pertussis vaccine, leading to its widespread adoption and abandoning the use of X-rays for the treatment of pertussis.2 Approximately 20 papers were published in 13 years, elaborating the therapeutic use of X-ray for pertussis. Table 1 summarizes key findings of these papers, while Table 2 provides a brief set of quotations from a sampling of these papers, permitting the authors to offer their perspectives on how effective they believed these treatments were. Over this time nearly 1500 patients were treated with X-rays, with over 75% being children. With 1 exception, the papers were uniformly consistent in concluding that the X-ray treatments were highly successful in the treatment of those of all ages. In the only study not showing a “successful” treatment, it was not possible to conclude that the X-ray treatment actually was not effective due to limitations of study design. This is because during the experiment the 22 X-ray treated patients was compared to a group receiving the drug antipyrene, with both showing a comparable improvement, no unexposed control group was employed.

Treatment efficacy via the use of X-ray therapy was higher with younger age-groups. In the experience of Bowditch and
| Citation | Date | Cases | Gender | Age                  | Stage of Disease                        | Doses                              | Exposure            | Results                                           |
|----------|------|-------|--------|----------------------|-----------------------------------------|-------------------------------------|---------------------|--------------------------------------------------|
| Bowditch and Leonard⁴ | 1923 | 26    | NA     | 3 months to 40 years | Probably all stages, 1 to 10 weeks      | 3 to 4 doses at intervals of 2 to 3 days | Dosage regulated by age of patient, total dose under an erythema dose (ED) | Quick cure 15% to 20%; gradual improvement 70%; no recovery 10% to 15% |
| Kingston and Faber⁶ | 1923 | 24    | NA     | 7 months to 13 years | All stages of the disease, 3 to 30 days duration when treatments were given | 1 to 3 doses at weekly intervals | 1/4 ED               | 4/24: immediate remarkable improvement; 2/24: not helped after 3 treatments; 10/24: markedly better after 2 treatments; 8/24: gradual improvement but not cured after 3 treatments |
| Cook⁸ (given in McKibben, 1927) | 1923 | 6     | NA     | 2 to 5 years and 1 adult | NA                                      | 1 to 3 treatments                  | 1/9 ED               | Considered a practical success; recommended further testing |
| Struthers¹³ | 1924 | 48    | NA     | 3 months to 30 years | Day 2 to week 8 (based on spasmodic episodes) | Two modes of treatment: (1) short exposures on alternate days 2 to 3 treatments; (2) with a single large dose 3 treatments: given on alternate days, possible second set of treatments, after a 10-day interval | Not given            | 7/48 (15%): prompt cure (within 24 to 48 hours); 20/48 (45%): relieved 4 to 5 days; 18/48 (40%): no appreciable improvement, believed the duration shortened |
| Bowditch¹⁰ | 1924 | 300   | NA     | Early weeks of age to 50 years; 30% <2 years; 70% <6 years | All stages of the disease present, 2 to 10 weeks | 4 exposures were less than 1/2 ED | More than 80% benefited from the treatment |
| Bowditch et al¹¹ | 1924 | 20    | NA     | <1 year (6); 1 to 2 years (4); 2 to 3 years (8); >3 years (2) | All stages of the disease               | NA                                 | Not given            | 20 patients had 288 severe paroxysms: By day 5 after treatment – 157 paroxysms and much less in severity. After 2 weeks, only 43 were noted |
| Leonard⁹ | 1924 | 400 plus 200 unexposed controls | NA     | NA                  | 4 treatments every other day unless showing rapid response | 1/3 ED               | X-rays relieved symptoms in >75% treated. Children treated had nearly 100% success. Average duration of disease in treated group was 5.5 weeks, whereas it was 8.7 weeks in the controls |
| Rhinehart¹⁴ | 1924 | 40    | NA     | NA                  | NA                                      | NA                                 | NA                  | Specific data not averaged, however, selected patients showed considerable benefit |
| Smith and Kirby¹² | 1924 | 20    | NA     | 4 weeks to 7 years | NA                                      | 1/2 ED               | NA                  | 2/100 have excellent improvements; 40% distinctly benefited; 24/100 displayed little/no improvement |
| Black¹⁷ (cited in Hess¹⁸ summary section) | 1925 | 100   | NA     | NA                  | NA                                      | NA                                 | NA                  | (continued)                                      |
### Table 1. (continued)

| Citation                        | Date  | Cases | Gender | Age                | Stage of Disease                  | Doses                  | Exposure | Results                                      |
|---------------------------------|-------|-------|--------|--------------------|-----------------------------------|------------------------|----------|----------------------------------------------|
| Friedman19                      | 1925  | 2     | 1 infant; 1 female | 14 months; 6 years | Chronic (2 years) and (6 months duration) | Up to 3 treatments | NA       | Both cases improved substantially during treatment, success after 2 series, probably due to total exposures |
| Leonard20                       | 1925  | 20    | NA     | 18 patients were <3 years old | 17 in first 3 weeks of disease, average 2.5 weeks at admission | Same dose as Leonard9; 3 treatments at 48 hour intervals; some patients were administered 2 or 3 sets of 3 treatments | Approximately 2/3 ED per set of 3 | There was a significant decrease in disease incidence and severity. These findings had the same values (and most the same patients) as reported in Bowditch et al |
| Faber and Struble21             | 1925  | 22 cases and 22 controls | NA | 2.9 years of age for cases | 9.4 days of paroxysms prior to treatment | Dose varied by age of patient | ≤1 ED | There was no treatment-related effect as compared to the control group |
| Bowditch and Smith3             | 1925  | NA    | NA     | NA                 | NA                                | NA                     | NA       | Review of post-Bowditch findings |
| Smith5                          | 1925  | 850   | NA/    | 750 children < 7 years; 260 children < 2 years | Multiple stages of disease (most in paroxysmal stage) | 3 to 4 doses at intervals of 2 to 3 days | Dosage based on age of patient, with total dose less than 1 ED | Approximately 80% of the cases displayed a lessening of the number and severity of the paroxysms in a time interval ranging from a few hours to 7 to 10 days |
| Hess22                          | 1926  | 102   | NA     | <1 to 10 years | Multiple stages treated | Doses 1 to 4 each separated by 5 to 9 days | NA | Recommended treatment to start at paroxysmal stage |
| Alexander23                     | 1927  | NA    | NA     | NA                 | NA                                | NA                     | NA       | Review of literature |
| De Puelles24                    | 1924  | This study was not translated into English | NA | NA                 | NA                                | NA                     | NA       | Reports successful treatments |
| Boner25                         | 1924  | 6     | NA     | 8 months to 7 years | This study was not translated into English | NA                     | NA       | Reports successful treatments |
| Sheriden26                      | 1927  | 22    | NA     | NA                 | NA                                | NA                     | NA       | 50% showed marked improvement within a few days. The rest showed moderate improvement in 2 weeks. Nearly all 22 cases were very severe and most had been whooping 2 to 8 weeks |
| Samuel27                        | 1929  | NA    | NA     | NA                 | NA                                | NA                     | NA       | Review paper |
| Von Meysenburgh28               | 1933  | 21    | NA     | ≥6 weeks | Multiple stages of disease | 1 to 4 exposures | NA | 15 of 21 required only 1 of 2 treatments; treatments were generally very effective |
| Liebman16                       | 1936  | >300  | NA     | NA                 | NA                                | 1 to 4 exposures | 1/4 to 1/5 ED | 80% of children were relieved and benefited; less than half of the remaining 20% failed to respond |

Abbreviation: NA, not applicable.
Table 2. Quotations by Leading Researchers on the Effectiveness of X-Ray Treatments for Pertussis.

| Reference                      | Quotes                                                                 |
|-------------------------------|------------------------------------------------------------------------|
| Bowditch and Leonard<sup>4(p313)</sup> | While our evidence so far is not sufficient to warrant any definite conclusions, we have the feeling that the X-ray at the present time may be of more value in the treatment of pertussis than any other form of treatment, including serum. We are certainly convinced of this fact—that it will not do to let this method of treatment drop, but that further careful scientific study should be made. |
| Kingston and Faber<sup>6(p429)</sup> | While the exact value, and limitations of the method demand further study, we feel that the definite improvement secured in many patients and the prompt and almost complete relief obtained in a few, constitute a positive gain in the treatment of a disease which is very rarely susceptible by other methods of more than temporary symptomatic relief. The fact that complete failure is met with in a certain proportion of cases should be explained in advance to the parents, but does not alter our belief that the X-ray treatment is at present the most promising therapeutic measure which we possess for pertussis. No ill effects from radiation have been encountered. |
| Smith<sup>5(p177)</sup> | An analysis of 850 cases of pertussis treated by the roentgen ray proves that: This means of therapy is of value in reducing the number and severity of the paroxysms and in shortening the course of the disease. The majority of the cases (750) occur under 7 years of age. Most of the patients (499) present themselves in the paroxysmal stage. The greatest benefit occurs in the paroxysmal stage, and especially in the younger patients. |
| Bowditch et al<sup>11(p222)</sup> | We have attempted to prove in two previous communications that in the roentgen ray we have a therapeutic agent for the treatment of whooping cough which is of definite value, and in our opinion, gives better results than any other single method of treatment. The object of this present paper is to present further evidence, which has been accumulating during the last year, of the beneficial action of this form of therapy. |
| Smith and Kirby<sup>12(p145)</sup> | No conclusions can be justifiably drawn from the small number of cases treated by us, but from published reports (3), it would appear that the roentgen ray offers a new hope in the treatment of whooping cough. In view of the rather wide prevalence of pertussis, it is earnestly suggested that where X-ray laboratories are available, physicians should employ the treatment. It is advised to begin treatment early, alternate radiation over chest and back at three and five-day intervals for three treatments and reradiate later if necessary. |
| Struthers<sup>13(p142)</sup> | From our results, however, we do feel that x-ray radiation in full doses has a definite place in the therapy of this most distressing disease of childhood. I know of no other method of treatment which gives equally good results. |
| Bowditch and Smith<sup>10(p1424)</sup> | In summarizing, the work of the past two years of the Boston Floating Hospital in the treatment of whooping cough by X-ray seems to have proved that there is a very distinct benefit to be derived by this method; that the paroxysms are definitely reduced in frequency and severity; that the enlargement of the hilus lymph nodes and the peribronchial thickening are definitely reduced; that the lymphocyte count, both relatively and absolutely, is similarly reduced, and that this method offers more constant results than any of the usual means of medication. |
| Smith and Kirby<sup>12(p145)</sup> | The benefits to be derived from roentgen therapy of pertussis are primarily a very prompt relief of the paroxysms of coughing with the attendant vomiting. This usually occurs shortly after the first exposure and it is the outstanding feature, because with the paroxysmal coughing eliminated, the remaining cough which may still occur is of no great importance. In the majority of cases there is a distinct shortening of the usual long-drawn out course of the disease and the associated complications are, as a rule, absent, owning to the relief of the cough. |
| Von Meyenburg<sup>28(p567)</sup> | In conclusion, I wish to state that in x-ray treatment of pertussis we have available the most effective agent for relieving the distressing symptoms of the disease, shortening its course and preventing the dangerous complications which are often encountered. |
| Liebman<sup>16(p646)</sup> | Seven hundred children with persistent cough were treated with roentgen radiation. This form of treatment was found to be of distinct value when the cough was either an aftermath of pertussis or subsequent to an acute upper respiratory tract infection. |
Dose of X-Ray Treatment of Pertussis

The dose of radiation employed in all reviewed studies was noted to be less than 1 ED. Only the Liebman study \(^{16}\) provided a specific conversion into rad units, with his dose range being from 1/4 to 1/5 ED (135-225 rad). Using information provided in 7 papers, \(^{6,10,12,16,21,22}\) a dose reconstruction was made using the RadPro software and making several reasonable assumptions depending on the study. These reconstructions confirmed that all doses were below the ED as indicated by the authors. The doses ranged across these 7 studies from a low of \(^{27}\) to a high of 430 to 450 rad. \(^{21,22}\) Doses were typically reduced by 50% to 70% in infants/very young children to the 50- to 60-rad dose range. \(^{10,27}\) It is of interest that Faber and Struble \(^{21}\) noted that “our single and total dosages appear to have been considerably larger than those of Bowditch and Leonard” (p. 816). This was the case for both dose rate and total dose. This conclusion would be consistent with the dose reconstruction presented here. It is unknown what the dose response may be for patients of different ages and gender as this was also confounded in the present series of papers by the existence of different disease stages and severity, all of which might affect treatment efficacy.

Discussion

Strengths and Limitations of Available Evidence

The clinical investigations revealed a range of strengths and limitations. On the strength side was the fact that most of the investigators were highly experienced clinicians with considerable knowledge of pertussis. They also worked closely with radiology experts. The patients do not appear to have been selected with any biased criteria. Usually, the cases were consecutively obtained and enrolled in the study. The studies, therefore, broadly included those of differing ages, gender, ethnicity, health status, and stage of disease. The most significant methodological limitation that was recognized was the lack of a concurrent control group in these studies. There were only 2 studies which reported the presence of concurrent control groups. One study was relatively small with only 22 treatment and 22 control individuals. \(^{21}\) The other study reported some 400 treatment cases and 200 control group individuals. \(^{9}\) Leonard \(^{9}\) did not report details on characteristics and the basis of selection of the control group. However, Leonard \(^{9}\) did report that the treated cases had an average disease duration of 5.5 weeks as compared to 8.7 weeks for the control. These findings indicate shortening of the illness by 3.2 weeks or nearly 40%. In the smaller study by Faber and Struble, \(^{21}\) the control was generally selected by alternating patient’s enrollment into the study. However, the investigators failed to follow their limited protocol on 5 different occasions that intentionally directed more severe cases into the X-ray group. None of these studies were blinded.

Thus, the lack of control groups in the overall database, and even the 2 studies reporting such controls, did not assist in a significant manner in the assessment of the findings. There was also a type of quasi control reported in the 1936 study of Liebman. \(^{16}\) He noted that at the start of the study cases treated with either UV or X-ray radiation were directly compared. After the first 10 patients for both groups were compared, the X-ray-treated patients fared so much better than the UV patients (data not shown in the Liebman study for the 20 patients) that they switched the treatment of all cases entirely to X-rays. Lacking the general presence of a concurrent control group, the researchers in this area of X-ray treatment effects on pertussis were left to infer the occurrence of a treatment-related effect when the cases displayed noticeable and quick relief from the various symptoms in a manner that substantially exceeded their professional experience.

A second issue of some importance that could affect judgment on the success of the treatment was the fact that a definite diagnosis of pertussis was difficult. This was due to reduced sensitivities of the diagnostic tests in the later stages of the illness. Since patients were treated at different stages, some patients would be negative for the presence of the causative agent. Thus, the diagnosis was often made based on the patient history, physical symptoms, diagnostic X-rays, and the experience of the treating physician.

Treatment Protocol Variation

The treatment technique, which originated with the initial publication of Bowditch and Leonard, \(^{4}\) included the radiation of the anterior chest for the first session, followed by the second session on the posterior chest on alternative days. In a third and usually final session, it was applied on the anterior chest. Other investigators would subsequently modify this protocol such that both anterior and posterior X-rays were administered during the same session. Others also reduced the multiple exposure sessions to only 1 session with a single larger dose. Finally, in the case of multiple treatments, the duration between treatments could be varied from alternate days, up to 1 treatment per week. Despite such differences in exposure protocols over time, the clinical responses were generally similar across studies, suggesting that the effects were independent of exposure interval duration.

Optimizing Dose

The concept of radiation-induced mutation was not discovered until the findings of Muller, \(^{29}\) with fruit flies. Linkage of X-ray exposure to enhancement of childhood associated tumors would not emerge until after X-ray treatments for pertussis had ended. However, the issue of whether children who were...
exposed to X-rays for the treatment of pertussis might experience an enhanced cancer risk was raised approximately 5 decades later by Webber, who stated that “it is generally unappreciated by physicians that during the two decades from 1920-1940, hundreds of children received potentially carcinogenic doses of radiation therapy to the thorax for whooping cough” (p. 449). Webber concluded by raising the issue that as of the 1970s hundreds of adults may have potentially enhanced risk of thyroid cancer due to the radiation treatment during infancy for pertussis.

These speculative comments of Webber are interesting but impossible to assess for multiple reasons. First, there is no record of which patients were lead shielded and the nature of the shielding protocol, if any. It is also unlikely that adult patients may even know that they were irradiated as an infant. Furthermore, the nature of the exposures were limited to generally 1 to 3 treatments, making any possible risks difficult to detect, especially with a very small sample size.

Mechanisms

The theoretical foundation for the use of X-ray treatment for pertussis, according to Bowditch, was based upon the same reasons for its use in bronchitis, that is, the proposed involvement of the hilum lymph nodes in an acute inflammatory hyperplasia. In theory, the X-ray treatment reduced the inflammation, reducing the size of these glands. Although focused mechanistic research of this issue was not undertaken during this era, considerable recent research has indicated that X-ray treatment in the general range of that used to treat pertussis induces an anti-inflammatory phenotype in multiple animal models. The radiation-induced anti-inflammatory phenotype has been extensively documented, being reported in a broad range of biological models. These findings suggest that this result may be broadly generalizable. These studies typically explored the underlying molecular mechanisms. Despite the broad range of biological models, consistent molecular patterns (Table 3) were reported that lead to the anti-inflammatory phenotype. Of particular significance is that the radiation-induced impact of disease end points was typically biphasic, showing decreases in disease-related responses at low doses, whereas at higher exposure levels adverse/undesirable health effects were typically noted. These findings have been hypothesized to provide a possible basis for the capacity of X-rays to affect therapeutic benefits on multiple diseases such as gas gangrene, inner ear infections/deafness, sinusitis, shoulder tendinitis/bursitis, arthritis, pneumonia, bronchial asthma, and caruncles and furuncles. Whether such X-ray-induced biphasic dose responses mediated the therapeutic effects seen with pertussis is unknown, but a reasonable potential hypothesis, especially for those radiotherapeutic interventions which involved relatively low-level irradiations applied in fractions with sufficiently long intervals permitting the repair of inflammation-induced tissue injury.

Table 3. Radiation-Induced Changes Leading to the Development of an Anti-Inflammatory Phenotype in Multiple Biological Models.

| End Point | Radiation Treatment Effect | References |
|-----------|---------------------------|-------------|
| NO/iNOS | Decrease                  | Hildebrandt et al, Ding et al, Schaeu et al |
| ROS     | Reduction                 | Hildebrandt et al, Schaeu et al, Nakatsukasa et al |
| HO-I    | Enhancement               | Schaeu et al, Nakatsukasa et al |
| Apoptosis| Induction                 | Kern et al, Huynh et al, Ren et al, DosReis and Lopes, Ferri et al, Perruche et al, Esmann et al |
| TGF-β1  | Suppression               | Schaeu et al, Nakatsukasa et al |
| TGF-β2  | Enhancement               | Schaeu et al, Nakatsukasa et al |
| NF-kB and AP-1 | Activation of transcription factors | Martin et al, Rödel et al |
| Leucocytes and PMNs | Decreased adhesion to endothelial cells | Arenas et al, Trott and Kamprad, Kern et al, Rödel et al |
| T-regulatory cells | Enhancement | Nakatsukasa et al, Weng et al |

Abbreviations: AP-1, activating protein 1; HO-1, heme oxygenase 1; iNOS, inducible nitric oxide synthase; NF-kB, nuclear factor kappa B; NO, nitric oxide; PMNs, polymorphonuclear neutrophils; ROS, reactive oxygen factor; TGF, tumor growth factor.

Author’s Note

The US government is authorized to reproduce and distribute for governmental purposes notwithstanding any copyright notation thereon. The views and conclusions contained herein are those of the author and should not be interpreted as necessarily representing policies or endorsements, either expressed or implied. Sponsors had no involvement in study design, collection, analysis, interpretation, writing, and decision to and where to submit for publication consideration.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research has been supported by awards from the US Air Force and ExxonMobil Foundation.

Note

1. The first apparent reported case of X-ray treatment of pertussis was mentioned by multiple authors in the X-ray pertussis literature of 1923 to 1936 cited in this article. However, none of these authors provided the specific reference(s) which was said to be in the
Russian scientific literature. They did provide a range of differing dates from 1907 to 1911.

**References**

1. Henry JE. A brief statistical study of recent experience with measles and whooping cough in Massachusetts. *Am J Public Health (N Y).* 1921;11(4):302-306.
2. Geier D, Geier M. The true story of pertussis vaccination: a sordid legacy? *J Hist Med Allied Sci.* 2002;57(3):249-284.
3. Bowditch HI, Smith L. Roentgen ray treatment of whooping cough. *Trans Am Clin Climatol Assoc.* 1925;41:53-64.
4. Bowditch HI, Leonard RD. Preliminary report on the treatment of pertussis by the X-ray. *Bos Med Surg J.* 1923;188(10):312-313.
5. Smith LW, Kirby AC. Some observations on the use of the X-rays in the treatment of pertussis by the roentgen ray. An analysis of eight hundred and fifty cases. *JAMA.* 1925;85(3):171-177.
6. Kingston JJ, Faber HK. Notes on the X-ray treatment of whooping cough. *Cal State J Med.* 1923;21(10):429-430.
7. McKibben W. The treatment of whooping cough in private practice. *Bos Med Surg J.* 1923;189(10):339-348.
8. Cook P. Personal communication. Cited in McKibben; 1923, page 345, 1923.
9. Leonard RD. Use of the roentgen ray in pertussis. *Am J Roentgenol Rad Ther.* 1924;11:264-267.
10. Bowditch HI. Further notes on the treatment of pertussis by the roentgen ray. *JAMA.* 1924;82(18):1422-1424.
11. Bowditch HI, Leonard RD, Smith LW. Studies on the roentgen-ray treatment of whooping cough. *Am J Dis Child.* 1924;28(3):322-328.
12. Smith M, Kirby AC. Some observations on the use of the X-rays in the treatment of pertussis. *J Arkansas Med Soc.* 1924;21:143-146
13. Struthers RR. X-ray treatment of pertussis. *Can Med Assoc J.* 1924;142:141-142.
14. Rhinehart DA. Comment in Smith and Kirby, 1924; discussion 145.
15. Percy KG. In McKibben, 1923; discussion 347.
16. Liebman C. Roentgen radiation treatment of chronic cough occurring during childhood. *Can Med Assoc J.* 1936;35(6):643-646.
17. Black RA. Personal communication. Cited in Hess. 1925;4:5.
18. Hess JH. The treatment of pertussis by roentgen-ray. *Ill Med J.* 1925;48:215-219.
19. Friedman LJ. X-ray therapy of chronic cough in children. *Arch Pediatr.* 1925;42:208-210.
20. Leonard RD. Further observations on the use of the roentgen ray in pertussis. *Am J Roentgenol Rad Ther.* 1925;13:420-423.
21. Faber KH, Struble HP. Does roentgen ray modify the course of whooping cough? *JAMA.* 1925;85(11):815-818.
22. Hess JH. The treatment of pertussis by roentgen ray. *J Iowa State Med Soc.* 1926;16(1):29-33.
23. Alexander WG. The X-ray in children. *Wisconsin Med J.* 1927;26(9):441-449.
24. De Puelles R. Roentgenotherapy of whooping cough. *Arch Exp Ped.* 1924;8:614-615.
25. Boner L. Fait Cliniques. Sur le traitement de la coqueluche par la radiotherapie. *J Radiol.* 1924;VIII(I):509.
26. Sheridan WM. X-rays in the treatment of pertussis. *Rad Rev.* 1927;4:5.
27. Samuel EC. Roentgen therapy of pertussis. *South Med J.* 1929;22(6):548-550.
28. Von Meyenburgh L. X-ray therapy of pertussis. *South Med J.* 1933;26(6):565-568.
29. Muller HJ. Artificial transmutation of the gene. *Science.* 1927;66(1699):84-87.
30. Webber BM. Radiation-therapy for pertussis. Possible etiologic factor in thyroid-carcinoma. *Ann Intern Med.* 1977;86(4):449-450.
31. Calabrese EJ, Calabrese V. Low dose radiation therapy (LD-RT) is effective in the treatment of arthritis: animal model findings. *Intern J Rad Biol.* 2013a;89(4):287-286.
32. Calabrese EJ, Calabrese V. Reduction of arthritic symptoms by low dose radiation therapy (LD-RT) is associated with an anti-inflammatory phenotype. *Int J Radiol.* 2013b;89(4):287-286.
33. Hildebrandt G, Seed MP, Freemantle CN, Alam CA, Colville-Nash PR, Trott KR. Effects of low dose ionizing radiation on murine chronic granulomatous tissue. *Strahlenther Onkol.* 1998;174(11):580-588.
34. Hildebrandt G, Seed MP, Freemantle CN, Alam CA, Colville-Nash PR, Trott KR. Mechanisms of the anti-inflammatory activity of low-dose radiation therapy. *Int J Rad Biol.* 1998b;74(3):367-378.
35. Ding AH, Nathan CF, Stuehr DJ. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. *J Immunol.* 1988;141(7):2407-2412.
36. Schae D, Marples B, Trott KR. The effects of low-dose X-irradiation on the oxidative burst in stimulated macrophages. *Int J Rad Biol.* 2002;78(7):567-576.
37. Schae D, Jahn J, Hildebrandt G, Trott KR. Radiation treatment of acute inflammation in mice. *Int J Rad Biol.* 2005;81(9):657-667.
38. Nakatsukasa H, Tsukimoto M, Ohshima Y, Tago F, Masada A, Kojima S. Suppressing effect of low-dose gamma-ray irradiation on collagen-induced arthritis. *J Radiat Res.* 2008;49(4):381-389.
39. Kern P, Keilholz L, Forster C, Seegenschmiedt MH, Sauer R, Herrmann M. In vitro apoptosis in peripheral blood mononuclear cells induced by low-dose radiotherapy displays a discontinuous dose-dependence. *Int J Radiat Biol.* 1999;75(8):995-1003.
40. Huynh MLN, Fadok VA, Henson PM. Phosphatidylinerse-dependent ingestion of apoptotic cells promotes TGF-β1 secretion and the resolution of inflammation. *J Clin Invest.* 2002;109(1):41-50.
41. Ren Y, Xie Y, Jiang G, et al. Apoptotic cells protect mice against lipopolysaccharide-induced shock. *J Immunol.* 2008;180(7):4978-4985.
42. DosReis GA, Lopes MF. The importance of apoptosis for immune regulation in Chagas disease. *Mem Inst Oswaldo Cruz.* 2009;104(suppl 1):259-262.
43. Ferri LA, Maugeri N, Rovere-Querini P, et al. Anti-inflammatory action of apoptotic cells in patients with acute coronary syndromes. *Artherosclerosis.* 2009;205(2):391-395.
44. Perruche S, Saas P, Chen W. Apoptotic cell-mediated suppression of streptococcal cell wall-induced arthritis is associated with alteration of macrophage function and local regulatory T-cell increase: a potential cell-based therapy. *Arthritis Res Ther.* 2009;11(4):R104.

45. Esmann L, Idel C, Sarkar A, et al. Phagocytosis of apoptotic cells by neutrophil granulocytes: diminished proinflammatory neutrophil functions in the presence of apoptotic cells. *J Immunol.* 2010;184(1):391-400.

46. Martin M, Vozenin MC, Gault N, Crechet F, Pfarr CM, Lefaix JL. Coactivation of AP-1 activity and TGF-beta 1 gene expression in the stress response of normal skin cells to ionizing radiation. *Oncogene.* 1997;15(8):981-989.

47. Rödel F, Keilholz L, Herrmann M, et al. Activator protein 1 shows a biphasic induction and transcriptional activity after low dose X-irradiation in EA.hy.926 endothelial cells. *Autoimmunity.* 2009;42(4):343-345.

48. Arenas M, Gil F, Gironella M, et al. Anti-inflammatory effects of low-dose radiotherapy in an experimental model of systemic inflammation in mice. *Int J Radiat Oncol Biol Phys.* 2006;66(2):560-570.

49. Arenas M, Gil F, Gironella M, et al. Time course of anti-inflammatory effect of low-dose radiotherapy: correlation with TGF-β1 expression. *Radiother Oncol.* 2008;86(3):399-406.

50. Trott KR, Kamprad F. Radiobiological mechanisms of anti-inflammatory radiotherapy. *Radiother Oncol.* 1999;51(3):197-203.

51. Kern PM, Keilholz L, Forster C, Hallmann R, Herrmann M, Seegenschmiedt MH. Low dose radiotherapy selectively reduces adhesion of peripheral blood mononuclear cells to endothelium in vitro. *Radiother Oncol.* 2000a;54(3):273-282.

52. Kern PM, Keilholz L, Forster C, et al. UVB-irradiated T-cells undergoing apoptosis lose 1-selectin by metalloprotease-mediated shedding. *Int J Rad Biol.* 2000b;76(9):1265-1271.

53. Rödel F, Hantschel M, Hildebrandt G, et al. Dose-dependent biphasic induction and transcriptional activity of nuclear factor kappa B (NF-κB) in EA.hy.926 endothelial cells after low-dose X-irradiation. *Int J Rad Biol.* 2004;80(2):115-123.

54. Rödel F, Kamprad F, Sauer R, Hildebrandt G. Low-dose radiotherapy: molecular and functional aspects [in German]. *Strahlenther Onkol.* 2002;178(1):1-9.

55. Nakatsukasa H, Tsukimoto M, Tokunaga A, Kojima S. Repeated y irradiation attenuates collagen-induced arthritis via up-regulation of regulatory T cells but not by damaging lymphocytes directly. *Radiat Res.* 2010;174(3):313-324.

56. Weng L, Williams RU, Vieira PL, Screaton G, Feldmann M, Dazzi F. The therapeutic activity of low-dose irradiation on experimental arthritis depends on the induction of endogenous regulatory T cell activity. *Ann Rheum Dis.* 2010;69(8):1519-1526.

57. Calabrese EJ, Dhawan G. The role of X-rays in the treatment of gas gangrene: a historical assessment. *Dose Response.* 2012;10(4):626-643.

58. Calabrese EJ, Dhawan G. Historical use of X-rays: treatment of inner ear infections and prevention of deafness. *Hum Exp Toxicol.* 2014;33(5):542-553.

59. Calabrese EJ, Dhawan G. The historical use of radiotherapy in the treatment of sinus infections. *Dose Response.* 2013;11:469-479.

60. Calabrese EJ, Dhawan G, Kapoor R. Use of X-rays to treat shoulder tendonitis/bursitis: a historical assessment. *Arch Toxicol.* 2014;88(8):1503-1517.

61. Calabrese EJ, Dhawan G. How radiotherapy was historically used to treat pneumonia: could it be useful today? *Yale J Biol Med.* 2013b;86(4):555-570.

62. Calabrese EJ, Dhawan G, Kapoor R. The use of X rays in the treatment of bronchial asthma: a historical assessment. *Radiat Res.* 2015;184(2):180-192.

63. Calabrese EJ. X-ray treatment of carbuncles and furuncles (boils): a historical assessment. *Hum Exp Toxicol.* 2013;32(8):817-827.